Major pharma eyes mid-priced biotech M&A deals in 2013

01/11/2013 | Xconomy

Big drugmakers with expired patents on major products will increasingly depend on mergers and acquisitions to increase sales, according to an analysis from Ernst & Young. Demand is expected to be high for biotech firms in the $5 billion to $20 billion range, particularly for "bolt-on" operations that can contribute to sales immediately.

View Full Article in:

Xconomy

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA